Granulocyte-macrophage colony-stimulating factor (GM-CSF) ameliorates chemotherapy-induced neutropenia in children with solid tumors

Pediatric Hematology and Oncology

Volumn 14, Issue 6, 1997, Pages 539-545

  Joost Van Pelt, L ^a   De Craen, Anton J M ^a   Langeveld, Nelia E ^a   Weening, Ron S ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b EMMA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

GM CSF; Neutropenia; Solid tumors

Indexed keywords

ANTINEOPLASTIC AGENT; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; DOSE TIME EFFECT RELATION; DRUG TOLERABILITY; EWING SARCOMA; FEVER; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION RISK; NEUTROPENIA; OSTEOSARCOMA; RHABDOMYOSARCOMA; RISK FACTOR; SOLID TUMOR; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 9844246996     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.3109/08880019709030910     Document Type: Article

References (13)

1. Metcalf D. The molecular biology and functions of the granulocyte-macrophage colony-stimulating factors. Blood. 1986;67:257-267.
2. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2). N Engl J Med. 1992;327:99-106.
3. Harmenberg J, Hoglund M, Hellstrom Lindberg E. G- and GM-CSF in oncology and oncological haematology. Eur J Haematol Suppl 1994;55:1-28.
4. Furman WL, Fairclough DL, Huhn RD, et al. Therapeutic effects and pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in childhood cancer patients receiving myelosuppressive chemotherapy. J Clin Oncol. 1991;9:1022-1028.
5. Saarinen UM, Hovi L, Riikonen P, Pihkala J, Juvonen E. Recombinant human granulocyte-macrophage colony-stimulating factor in children with chemotherapy-induced neutropenia. Med Pediatr Oncol. 1992;20:489-496.
6. Marina NM, Shema SJ, Bowman LC, et al. Failure of granulocyte-macrophage colony-stimulating factor to reduce febrile neutropenia in children with recurrent solid tumors treated with ifosfamide, carboplatin, and etoposide chemotherapy. Med Pediatr Oncol. 1994;23:328-334.
7. Burdach SEG, Müschenich M, Josephs W, et al. Granulocyte-macrophage colony-stimulating factor for prevention of neutropenia and infections in children and adolescents with solid tumors. Cancer. 1995;76:510-516.
8. Fink FM, Maurer Dengg K, Fritsch G, et al. Recombinant human granulocyte-macrophage colony-stimulating factor in septic neutropenic pediatric cancer patients: detection of circulating hematopoietic precursor cells correlates with rapid granulocyte recovery. Med Pediatr Oncol. 1995;25:365-371.
9. Moghrabi A, Fuchs H, Brown M, et al. Cyclophosphamide in combination with sargramostim for treatment of recurrent medulloblastoma. Med Pediatr Oncol. 1995;25:190-196.
10. Lachance DH, Oette D, Schold SCJ, et al. Dose escalation trial of Cyclophosphamide with sargramostim in the treatment of central nervous system (CNS) neoplasms. Med Pediatr Oncol. 1995;24: 241-247.
11. Nemunaitis JJ. RhGM-CSF in bone marrow transplantation: experience in pediatric patients. Med Pediatr Oncol Suppl. 1992;2:31-33.
12. Tapp H, Vowels M. Prophylactic use of GM-CSF in pediatric marrow transplantation. Transplant Proc. 1992;24:2267-2268.
13. Klingebiel T, Handgretinger R, Herter M, et al. Autologous transplantation with peripheral blood stem cells in children and young adults after myeloablative treatment: nonrandomized comparison between GM-CSF and G-CSF for mobilization. J Hematother. 1995;4:307-314.